Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis | MicrobiomeTrials← Back to trialsNCT07103863
Multimodal Radiomics Model (18F-FAPI PET/CT + CMR) for AL Cardiac Amyloidosis Prognosis
ENROLLING_BY_INVITATIONOBSERVATIONAL
Trial Details
Start: 2025-02-13Est. Completion: 2028-02-01
Enrollment target: 49 participants Locations- Beijing Anzhen Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
AmyloidCardiac AmyloidosisAmyloidosisHealthy Subjects
\[18F\]FT8, a derivative of 1-(4-pyridyl)-4-piperazinyl arene (\[18F\]TPZA), exhibits high affinity for AL amyloid in my…
Hefei, ChinaEst. completion Jul 20, 2028
Systemic Amyloidosis
The goal of this research study is to determine whether changes in organ-specific uptake of 124I- AT-01 can be measured …
Knoxville, United StatesCompleted Aug 1, 2023